张志荣, 何勤. 肝靶向万乃洛韦毫微粒的研究J. 药学学报, 1998, 33(9): 702-706.
引用本文: 张志荣, 何勤. 肝靶向万乃洛韦毫微粒的研究J. 药学学报, 1998, 33(9): 702-706.
Zhang Zhirong, He Qin. STUDY ON LIVER TARGETED VALACICLOVIR POLYBUTYLCYANOACRYLATE NANOPARTICLESJ. Acta Pharmaceutica Sinica, 1998, 33(9): 702-706.
Citation: Zhang Zhirong, He Qin. STUDY ON LIVER TARGETED VALACICLOVIR POLYBUTYLCYANOACRYLATE NANOPARTICLESJ. Acta Pharmaceutica Sinica, 1998, 33(9): 702-706.

肝靶向万乃洛韦毫微粒的研究

STUDY ON LIVER TARGETED VALACICLOVIR POLYBUTYLCYANOACRYLATE NANOPARTICLES

  • 摘要: 为提高核苷类药物对乙型肝炎的疗效并降低其毒性,用乳化聚合法制备了万乃洛韦聚氰基丙烯酸正丁酯毫微粒,对其形态、大小及其分布、体外释药特性、载药量、初步稳定性、动物体内的分布和体外肝细胞的摄取情况进行了研究。结果表明,该毫微粒粒径dav=104.77±11.78nm;载药量11.20%;包封率84.85%;体外释药符合双相动力学规律;对肝细胞具有通透性;静注后15min有74.49%集中在肝脏。提示,万乃洛韦毫微粒对于提高万乃洛韦对病毒性乙型肝炎的治疗效果和降低其对肾脏的毒性有意义。

     

    Abstract: The valaciclovir polybutylcyanoacrylate nanoparticles (VACA-PBCA-NP) were prepared by emulsion polymerization method. The morphology, size and size distribution, release characteristics in vitro, drug loading, stability and distribution of VACV-PBCA-NP in mice were studied. The results showed that the dav=104.77±11.78 nm, drug loading was 11.20%. The release characteristics in vitro was in accord with two-phase kinetics. 74.49% of the VACV were concentrated in liver at 15 min after iv VACA-PBCA-NP. The amount of VACV entering hepatocytes was also increased greatly. This research seems to have important value for increasing the anti-hepatitis B virus effect and decreasing toxicity of VACV.

     

/

返回文章
返回